10-Q quarterly report · filed Nov 5, 2026

Progyny, Inc. (PGNY) Q3 2026 10-Q Quarterly Report

Short answer

Progyny, Inc. (PGNY) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $341M (up 8.9% year over year) with net income of $26M.

Q3 2026 key financials · XBRL

Revenue
$341M
+8.9% YoY · −2.6% QoQ
Net income
$26M
+89.4% YoY · −6.4% QoQ
Operating margin
10.3%
Gross margin
24.5%
EPS (diluted)
$0.32
+113.3% YoY · −5.9% QoQ

Source: XBRL data from the Progyny, Inc. (PGNY) Q3 2026 10-Q on SEC EDGAR. USD.

Progyny, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $341.254M, up 9% YoY, fertility benefits $21.4M increase, Progyny Rx $6.5M increase
  • Gross margin 24.5% vs 23.2%, operating margin 10.3% vs 6.9% YoY
  • Net income $26.252M vs $13.864M, adjusted EBITDA margin 17.1% vs 17.5%
  • Cash $116.8M and marketable securities $78.8M at September 30, 2026
  • Nine-month operating cash flow $152.979M, share repurchases $230.9M at $23.83 average price

Risk Factors

  • Newly added guidance risk: November 4, 2026 fourth-quarter and full-year guidance exposed to revisions and consensus shortfalls
  • Most material regulatory update: February 3, 2026 PBM reforms require rebate disclosure, 100% consumer pass-through, reporting and audits
  • Competitive risk: Healthcare consolidation may shift clients toward integrated solutions and increase provider negotiating power
  • Operational risk: Specialty-pharmacy disruptions could delay fertility treatments and reduce Progyny Rx revenue
  • Concentration risk: Technology-industry clients represent a significant revenue share, despite no client exceeding 10% of revenue

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Progyny, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.